{"entity":{"id":"glp1-agonists-cancer-risk","kind":"technology","name":"GLP-1 receptor agonists and obesity-related cancer risk","aka":[],"tldr":"GLP-1 agonists, the new weight-loss injections, lower weight by 15-20%. Early observational data suggest fewer obesity-related cancers in people who take them, but no trial has yet tested cancer as an outcome.","summary":"Obesity is causally linked to at least 13 cancers (IARC 2016). Semaglutide and tirzepatide produce 15-22% weight loss in trials and reduce cardiovascular events (SELECT, NEJM 2023). Several large cohort and target-trial-emulation studies in people with type 2 diabetes report 10-40% lower incidence of obesity-associated cancers (notably endometrial, kidney, liver, pancreatic and colorectal) with GLP-1 receptor agonists compared with insulin or other glucose-lowering drugs, and a signal for lower cancer risk than bariatric surgery in one study; these are observational with short follow-up and prone to immortal-time and surveillance biases. Thyroid C-cell tumours in rodents led to a label warning, with no convincing human medullary thyroid cancer signal so far; pancreatitis and pancreatic cancer concerns have not been borne out. Because these drugs are now used by millions, a randomised trial with cancer incidence as a primary endpoint, or pre-specified cancer endpoints in ongoing outcome trials, is feasible and important.","status":"emerging","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/GLP-1_receptor_agonist","links":[{"label":"IARC Handbook: body fatness and cancer (NEJM 2016)","url":"https://doi.org/10.1056/NEJMsr1606602"},{"label":"SELECT (NEJM 2023)","url":"https://doi.org/10.1056/NEJMoa2307563"}],"tags":[],"related":["idea-prev-glp1-cancer-prevention-rct","idea-prev-glp1-endometrial-hyperplasia","idea-nl-glp1-adjuvant-hr-breast"],"cancers":["endometrial","colorectal","hcc","pancreatic","rcc","breast-hr-positive"],"sections":["nutrition-lifestyle","prevention"],"technologies":["bariatric-surgery-cancer-incidence","chemoprevention","dietitian-led-weight-loss-breast"],"targets":[],"drugs":[],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":["obesity-related-cancers","metabolic-syndrome","energy-balance","body-composition"],"trials":[],"people":[],"bottlenecks":["b-prevention-adoption","b-funding-allocation"],"keyPapers":["paper-lincoff-n-engl-j-med"],"journals":[],"dependsOn":[],"notes":[],"principle":"Sustained weight loss lowers adiposity-driven insulin, oestrogen and inflammatory signalling; GLP-1 receptor agonists may also have direct anti-proliferative or immunomodulatory effects independent of weight.","strengths":["First scalable pharmacological route to reversing the obesity-cancer risk","Consistent direction of observational signals","Cardiometabolic benefits already proven"],"limitations":["No randomised cancer endpoint","Observational biases","Cost, access and lean-mass loss with rapid weight reduction"]},"route":"/technologies/glp1-agonists-cancer-risk/","neighbours":{"idea":[{"id":"idea-prev-glp1-cancer-prevention-rct","kind":"idea","name":"A trial of GLP-1 weight-loss drugs with cancer as the primary outcome","route":"/ideas/idea-prev-glp1-cancer-prevention-rct/"},{"id":"idea-prev-glp1-endometrial-hyperplasia","kind":"idea","name":"GLP-1 drugs to reverse endometrial precancer in women with obesity","route":"/ideas/idea-prev-glp1-endometrial-hyperplasia/"},{"id":"idea-nl-glp1-adjuvant-hr-breast","kind":"idea","name":"GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer","route":"/ideas/idea-nl-glp1-adjuvant-hr-breast/"},{"id":"idea-nl-bariatric-cancer-registry-linkage","kind":"idea","name":"Link bariatric and GLP-1 registries to cancer registries in every country that has both","route":"/ideas/idea-nl-bariatric-cancer-registry-linkage/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"craniopharyngioma","kind":"cancer","name":"Craniopharyngioma","route":"/cancers/craniopharyngioma/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"section":[{"id":"nutrition-lifestyle","kind":"section","name":"Diet, Exercise & Lifestyle","route":"/fronts/nutrition-lifestyle/"},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"bariatric-surgery-cancer-incidence","kind":"technology","name":"Bariatric surgery and cancer incidence","route":"/technologies/bariatric-surgery-cancer-incidence/"},{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/"},{"id":"dietitian-led-weight-loss-breast","kind":"technology","name":"Dietitian-led weight-loss programmes in HR-positive breast cancer","route":"/technologies/dietitian-led-weight-loss-breast/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}],"term":[{"id":"body-composition","kind":"term","name":"Body composition (lean mass, fat mass, visceral fat)","route":"/terms/body-composition/"},{"id":"energy-balance","kind":"term","name":"Energy balance","route":"/terms/energy-balance/"},{"id":"metabolic-syndrome","kind":"term","name":"Metabolic syndrome and insulin resistance","route":"/terms/metabolic-syndrome/"},{"id":"obesity-related-cancers","kind":"term","name":"Obesity-related cancers (IARC list of 13)","route":"/terms/obesity-related-cancers/"}],"bottleneck":[{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/"},{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/"}],"paper":[{"id":"paper-lincoff-n-engl-j-med","kind":"paper","name":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","route":"/key-papers/paper-lincoff-n-engl-j-med/"}],"pathway":[{"id":"lipid-metabolism-cancer","kind":"pathway","name":"Lipid synthesis, uptake & cholesterol","route":"/pathways/lipid-metabolism-cancer/"}],"roadmap":[{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/"},{"id":"nutrition-lifestyle-roadmap","kind":"roadmap","name":"Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment","route":"/roadmaps/nutrition-lifestyle-roadmap/"}]}}